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Abstract 
Small molecule drugs and probes are important tools in drug discovery, pharmacology, and 
cell biology. This is of course also true for epigenetic inhibitors. Important examples for the 
use of established epigenetic inhibitors are the study of the mechanistic role of a certain target 
in a cellular setting or the modulation of a certain phenotype in an approach that aims towards 
therapeutic application. Alternatively, cellular testing may aim at the validation of a new 
epigenetic inhibitor in drug discovery approaches. Cellular and eventually animal models 
provide powerful tools for these different approaches but certain caveats have to be 
recognized and taken into account. This involves both the selectivity of the pharmacological 
tool as well as the specificity and the robustness of the cellular system. In this article, we 
present an overview of different methods that are used to profile and screen for epigenetic 
agents and comment on their limitations. We describe not only diverse successful case studies 
of screening approaches using different assay formats, but also some problematic cases, 
critically discussing selected applications of these systems. 
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Introduction 
Cellular models are important tools for the characterization of new small molecule drugs and 
chemical probes. Vice versa, well-defined chemical tools can be used to probe the 
mechanistic role of a defined target in a physiological or pathophysiological pathway. It is 
very important to know the abilities and limitations of both the cellular system and the small 
molecule. The small molecule may be designed as a biological tool or a therapeutic agent, 
functions that are overlapping but also have complementary requirements. To be successful, a 
drug needs to achieve a desired phenotype in patients, with a side effect profile that is 
tolerable. In the rational optimization of drug candidates, a strong mechanistic insight 
involving knowledge of target potency and selectivity is highly desirable but not absolutely 
necessary. Thus, a significant number of drugs are successfully used without a clear 
understanding of their mechanism of action while many others work through interactions with 
multiple targets. On the other hand, a chemical probe or tool compound needs to produce the 
expected biological effects in cellular models, ideally through a high affinity interaction with 
a single target. The review article of Arrowsmith et al.
1
 provides a detailed discussion on the 
differences between drugs and probes. For a high quality probe or pharmacological tool, for 
example, the Structural Genomics Consortium (SGC) has defined rigid requirements 
regarding selectivity and potency. 
One important consideration is the probe concentration to be used. The concentration required 
to demonstrate in vitro activity of the probe in mechanism-based assays for the desired target 
gives some guidance on the relevant doses for cellular studies. However, due to differences in 
uptake, stability, and efflux, the necessary concentrations for cellular studies may differ 
greatly between two compounds with similar in vitro potencies. Thus, ideally, a dose titration 
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should be performed and both the target engagement and selectivity should be analyzed 
before selecting the optimum concentration relevant for the phenotypic response, keeping in 
mind that only a narrow window might allow the observation of specific effects in a cellular 
setting. 
In this article, we provide an overview of different approaches for the cellular characterization 
of drugs and pharmacological probes, summarized in Fig. 1. Generally, these approaches are 
also used for testing the effect of genetic manipulation, e.g., by siRNA. The same restrictions 
of the cellular models will apply with regard to the interpretation of nucleic acid based 
interventions. In addition, the effect of chemical inhibition and knockdown or knockout will 
not necessarily be the same.
2
 With chemical inhibition, the protein is still present in the 
cellular network and able to interact with its partners, while a knockout removes it completely 
and the resulting phenotype may also stem from the alteration of scaffolding functions. For 
example, it was shown that histone deacetylase 6 (HDAC6) protein knockdown is not 
functionally equivalent to catalytic inhibition of its deacetylase activity in SKBR3 cells.
3
 
Another example of the separation of catalytic activity and scaffolding functions of an 
epigenetic modifier is the action of lysine specific demethylase 1 (LSD1) in myeloid leukemia 
cells. Here, it was proposed that the block of differentiation induced by LSD1 is independent 
from its demethylase activity. Surprisingly, inhibitors targeted at its demethylase activity were 
still able to relieve the block of differentiation. It is not clear, therefore, whether the inhibitor 
action is still dependent on intact amine oxidase activity of LSD1.
4
 Thus, to analyze the 
validity of a hypothesis regarding the function of an epigenetic protein, a rescue experiment 
with a dominant negative function, that is lacking the critical catalytic or recognition function, 
should be performed. A positive example is a study on the role of the methyl lysine binding 
protein Spin1 (Spindlin1) in liposarcoma, where re-expression of Spin1 rescued the knockout 
phenotype but expression of a mutant that cannot bind H3K4me3 failed to do so.
5
 This proves 
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the dependency of the phenotype on an intact trimethyl lysine recognition and provided 
significant rationale for drug discovery approaches targeting Spindlin1.
6,7
 
For pharmacological experiments, reference compounds and negative controls are very 
important. Ideally, the reference molecules should be derived from a different chemical 
scaffold to rule out structure specific off-target effects. For the same reason, it is ideal to have 
a negative control with a similar scaffold to the newly tested probe. For example, among the 
BRD4 inhibitors that are available from different chemical scaffolds
8
 the prototypic inhibitor 
(+)-JQ-1 and its inactive enantiomer (–)-JQ-1 can be tested side by side.9 The  SGC10 is 
providing many probes for epigenetic targets with detailed selectivity profiles and also 
negative controls.  
Here, we will present different methods that were useful for the cellular characterization of 
epigenetic probes and provide selected examples of their use, without the intention of being 
exhaustive in the coverage of the literature. This article is intended as a commentary and 
guideline for cellular studies using epigenetic inhibitors with representative examples.  
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Biochemical Assays 
Measurement of target-enzyme activity in cells or lysates 
Many of the biochemical assays that are used for in vitro assays can also be applied to cellular 
lysates or may even work in living cells. Generally, interactions with cellular proteins might 
disrupt the assay; therefore, the selectivity of the assay is of great importance. If an enzyme 
assay involves a substrate that can be converted by a range of similar enzymes, inhibition 
results have to be interpreted accordingly.  
 
Trypsin Assay 
The most widely used HDAC enzyme assays follow the histone deacetylase assay 
homogenous (HDASH) procedure.
11,12
. In this protocol, a derivative of acetyl lysine is 
deacetylated by the enzyme(s) and the product formation is measured by a subsequent 
detection step. This involves coupling with a protease, usually trypsin, which leads to 
liberation of the fluorophore AMC with a concomitant shift in fluorescence wavelength. 
Bonfils et al.
13
 discovered the cell permeability of the synthetic HDAC substrate Boc-Lys(ε-
Ac)-AMC (also termed MAL
14
) and developed a cellular version of the HDAC assay.
15
 Only 
after the substrate got deacetylated by active deacetylases in cells or lysates, the proteinase 
trypsin accepts the substrate and cleaves it to form the free fluorophore AMC that can be 
quantitated by fluorescence spectroscopy.
12
 When cells have been incubated with an inhibitor 
and, hence, HDACs are not active in the assay, the added synthetic substrate stays acetylated 
and no free fluorophore is liberated by trypsin cleavage, as illustrated in Fig. 2. Thus, the 
trypsin assay offers a simple method to measure HDAC activity directly in cells. As most 
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zinc-dependent HDACs accept MAL as substrate, the assay detects global HDAC activity 
with a moderate subtype selectivity towards some isoforms, such as HDAC6.
12
 Meanwhile 
NAD
+
-dependent deacetylases (sirtuins) can be excluded, as MAL is a poor substrate for 
these enzymes. The derivative ZMAL
15
 is converted by both HDACs and sirtuins, while 
analogues are available with some subtype preference in vitro,
16
 but this has not been applied 
widely to the cellular setting.
17
 
The coupled trypsin assay offers the determination of IC50-values for deacetylase inhibitors in 
cells. Since the assay is homogenous and can be performed in 96-well plates, high-throughput 
testing can easily be performed. However, since deacetylase inhibition reduce cell 
proliferation
19
, inhibitors have to be tested in a proliferation assay for the same incubation 
time and concentration, to ensure that effects do not arise due to reduced cell numbers. To 
avoid anti-proliferative effects in trypsin assays, incubation times are usually kept at shorter 
time scales (a few hours) as compared to antiproliferative tests (2-4 days). 
A similar assay, the HADC-Glo I/II, has recently been established for a 1536-well cell-based 
assay.
20
 In the assay, a cell permeable HDAC substrate is used that can be converted by a 
protease into a luciferase substrate upon deacetylation by endogenous HDAC I or II. 
 
Cellular thermal shift assay 
Most cellular assays do not measure target engagement directly, but involve readouts of 
downstream processes. For successful drug discovery efforts, direct target engagement of lead 
inhibitors should be examined early in the project. Nordlund et al.
21
 developed an assay to 
directly monitor target engagement of a drug in cells, the cellular thermal shift assay 
(CETSA). The underlying principle is the same principle as in thermal shift assays with 
recombinant isolated proteins.
22
 The target protein is put under thermal stress in a cellular 
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setting and specific inhibitors may lead to thermal stabilization. This can be performed both 
with lysates and intact cells. Generally, the temperature-dependent Gibbs free energy of 
unfolding ∆Gu determines protein stability. When proteins are exposed to increasing 
temperatures their ∆Gu usually decreases until it becomes zero at equilibrium, where the 
concentrations of unfolded and folded proteins are equal. The temperature at the equilibrium 
is referred to as the melting temperature of the specific protein. If a compound engages its 
target, it can induce a stabilization of the protein in the free energy of binding, which can 
result in increased ∆Gu and higher melting temperature of the protein will be measured.
22
 A 
schematic illustration of this effect is shown in Fig. 3. 
In a CETSA experiment, whole cells or lysates are aliquoted and heated to different 
temperatures. The amount of soluble protein in each aliquot can be quantified by different 
techniques, such as Western blotting, mass spectrometry, or Alpha Screen assays.
23
 The 
melting temperature is determined by the inflexion point of a curve plotted as temperature 
versus quantified soluble protein. The stabilizing effect when compounds bind to a protein is 
concentration and affinity dependent
22
, which enables to monitor drug concentration effects in 
an isothermal dose-response experiment (ITDRFCETSA). However, half-saturation points of 
this method are normally reached at higher concentrations than in standard dose-response 
experiments due to the applied temperatures that go beyond 37°C. Obtained values from 
ITDRFCETSA experiments would need further modulation for assessment of drug affinity at 
37°C. Nevertheless, dose-response effects can be examined with ITDRFCETSA experiments.
21
 
The procedure is time consuming and quite costly and, thus, usually not suitable for screening 
of larger numbers of compounds. Also, no functional inhibition is monitored and negative 
results do not exclude target engagement or inhibition of the target enzyme, as not all 
enzyme/inhibitor engagements increase ∆Gu upon binding. Here, a comparison with a 
reference inhibitor or ligand is very important. We have observed such a lack of effect with 
JmJD2A and known inhibitors of its catalytic domain (unpublished data). Thus, only positive 
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results are meaningful results, at least for new and so far untested target/inhibitor 
combinations. 
When the data of thermal shift assays are interpreted, it is valuable to consider the possible 
different reasons for stabilization. It can occur because of enthalpy and/or entropy effects and 
different ligands may exert different impact with respect to these effects. Larger temperature 
shifts were observed from more entropically-driven binding.
22
 Thus, it is difficult to quantify 
the affinity of compounds by their stabilization effect of a target and usually they are best 
used for ranking within a compound class with similar physicochemical properties.
24
 Still, 
models for the quantitative evaluation of thermal shift assays have been established
25,26
 and 
have also been applied to epigenetic targets, at least in vitro. An example is the binding of the 
ligand A366 to the methyl lysine binding protein Spindlin1.
6
  
 
Fluorescence recovery after photobleaching  
Fluorescence recovery after photobleaching (FRAP) is a method to quantify molecular 
binding interactions in living cells with fluorescent-labeled proteins (e.g., with GFP). A single 
fluorescent cell gets exposed to a high-intensity laser pulse, which induces a bleached spot on 
the cell without alterations of cell function or structure. At frequent intervals after the 
bleaching, fluorescence images at low laser intensity are taken to determine the rate at which 
fluorescent molecules relocate into the photo bleached spot. Collected data of a FRAP 
experiment are plotted by fluorescence intensity versus time. These recovery curves give 
information about diffusion and binding of the fluorescent protein to its targets in a cell. The 
degree of delaying the fluorescence recovery is dependent to the strength of binding. To 
examine if binding interactions and not only diffusion are involved in a FRAP recovery curve, 
the data of an inactive control protein have to be compared with that of active proteins. If 
  11 
recovery time of the curve with active protein is slower than that of the control, binding 
interactions are involved. Only if diffusion is much faster than binding interactions, it can be 
neglected. Diffusion-coupled or diffusion-uncoupled FRAP experiments require different 
mathematical data analysis methods.
27
 
When the fluorescent-labeled enzyme is inhibited by a compound, the binding to its natural 
target is impaired. This difference between inhibited and natural fluorescence recovery gives 
information on the engagement of the tested compound with the labeled target protein. 
Since epigenetic reader proteins do not have a catalytic activity, or such an activity is located 
at another domain of the target protein in question, many assays are not applicable. The FRAP 
technique offers a possibility to study target engagement in these proteins and has been 
applied, e.g., for potential bromodomain inhibitors. The bromodomain-containing protein of 
interest is labeled with GFP. When photobleaching has been applied, the rate of diffusion of 
unbleached proteins into the bleached region is limited by protein binding to chromatin or 
chromatin-associated complexes. This rate limiting step makes the movement of unbleached 
proteins in the bleached region slower than freely diffusible molecules. Therefore, the time 
needed until the bleached spot is recovered is related to protein affinity to the chromatin. If an 
inhibitor has bound to the bromodomain of interest, the time of recovery should increase.
28
 
Philpott et al.
28
 showed that FRAP assays are broadly applicable across bromodomains when 
half recovery times are determined for inhibitors. The method should also be applicable for 
inhibitor analysis for other reader proteins, like Tudor- or chromodomain-containing proteins 
that bind to proteins with methylated lysines.
29
 
Substrate analysis 
Immunodetection of protein modifications 
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Posttranslational modifications of histones and other substrate proteins by an epigenetic 
modifier with enzymatic activity offer the opportunity to examine the cellular activity via 
immunodetection with specific antibodies. Mostly, Western blots are performed, but also 
enzyme-linked immunosorbent assays (ELISAs), AlphaLISA
®
, and immunofluorescence 
microscopy are possible methods to globally quantify histone modifications. For the final 
quantitation, normally a secondary antibody labeled with a fluorophore or enzyme (e.g., HRP) 
is used. In commercially available AlphaLISA
® 
assays, the primary antibody is immobilized 
to acceptor beads. Donor beads are coated with streptavidin. Via a biotinylated antibody 
against the histone, acceptor beads and donor beads come in proximity. After laser irradiation 
of the donor beads, short-lived singlet oxygen gets released and only reaches acceptor beads, 
which are in proximity via the antibody binding. Singlet oxygen generates a 
chemiluminescent signal in acceptor beads which can be quantified. Highly specific primary 
antibodies are very important for reliable results, especially for histone methylation. The 
acetyl group on a lysine represents a bulky modification with a change in charge, which 
facilitates the development of specific antibodies for lysine acetylation, also on specific 
residues. In contrast, mono-, di-, and tri-methylated lysines differ only gradually in size and 
lipophilicity but not in charge and selective antibodies against one species (e.g., dimethylated 
lysine) are more difficult to obtain. Engelhofer et al. assessed over 200 antibodies for 
epigenetic targets and more than 25 % failed in specificity tests.
30
 Due to the lack of uniform 
standard antibody validation, a website (http://compbio.med.harvard.edu/antibodies/) to share 
experimental results on antibody specificity has been established by Engelhofer et al.
30
 Dot 
blot experiments to exclude cross-reactivity of the antibody with other histone modifications 
or unmodified histones should always be performed prior to immunodetection experiments.  
Western blot 
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Target engagement of histone deacetylase inhibitors has been supported in numerous 
publications via Western blots. Robust histone acetylation can be observed in cell lysates or 
histone extraction  by SDS-PAGE and Western blot with specific antibodies.
31
 In contrast, 
changes in global histone methylation, after treatment with methyltransferase or demethylase 
inhibitors, leads to conflicting results. Several publications show hypermethylation after 
incubation of cells with potential demethylase inhibitors. However, the protein bands in these 
blots are not always convincing in their intensity differences. For example, after LSD1 
knockout significant changes in histone methylation of H3K4me could not be shown via 
Western blots.
32,33
 Wang et al.
34
 recently reported that local changes in histone methylation 
could be observed after LSD1 inhibition, but global changes were not detected. Also Kruger 
et al.
35
 reported that they did not detect significant global changes in H3K4me1/2 levels after 
LSD1 inhibition. The reason for this effect is not clear. A potential factor could be that other 
proteins or molecules mask the modification, or demethylation is more site-specific. Observed 
global histone hypermethylation in Western blots after the treatment of cells with a (potential) 
demethylase inhibitor might appear due to off-target effects of the compound, especially when 
high concentrations are applied. However, local changes in the methylation level of histones 
near target genes could be revealed via immunoprecipitation in several publications.
35,36,4
 
In summary, target verification via the detection of posttranslational modifications, like 
histone acetylation or methylation is typically done by Western blot, but changes in global 
histone methylations have to be interpreted cautiously. Furthermore, Western blotting is a 
time consuming method and thus only allows a low throughput. ELISA type assays and 
AlphaLISA assays that also rely on the antibody-mediated quantitation of posttranslational 
effects are possible and allow a much higher throughput. One example of a successful 
screening campaign with ELISA assays led to the discovery of the HDAC6 inhibitor 
tubacin.
37
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Immunofluorescence, based on specific antibodies against a certain posttranslational histone 
modification, allows the quantitation of the modification level in single cells and can be 
applied to a large number of cells. After the measurement, the overall signal is corrected with 
regard to cell number, which enables the comparison of samples with different cell numbers. 
  
Since detection of global hypermethylation via Western blot might prove difficult, especially 
in this case, immunofluorescence is a viable alternative. King et al.
38
 developed an 
immunofluorescence assay with JumonjiD2-demethylase transfected cells. In addition, 
immunofluorescence assays without prior transfection of the cells have been published 
including EC50-values.
39,40
 
Chromatin immunoprecipitation (and variations of it) 
Chromatin is a complex of macromolecules found in the nucleus of a cell and consists of 
DNA, protein, and RNA. The primary structure of chromatin is the nucleosome, which is 
formed by an octamer of four different histone proteins, each present twice, and wrapped 
around by 146 base pairs of DNA. Gene expression regulation can be achieved through direct 
modification of the DNA with modified nucleobases, including 5-methylcytosine (5mC) and 
5-hydroxymethylcytosine (5hmC) or through histone posttranslational modifications (PTMs), 
including methylation, acetylation, phosphorylation, and ubiquitylation.
41
 Histone PTMs are 
key components of the epigenome and they can affect chromatin transcriptional output, as 
they can modulate interactions between histones and DNA and directly affect chromatin 
condensation. Moreover, histone PTMs also act as docking sites for proteins that can read the 
mark and recruit complexes to activate or repress transcription. Histone PTMs can show 
altered profiles in cancer cells or after drug treatment.
42
 
Chromatin immunoprecipitation (ChIP) is an invaluable method for studying interactions 
between specific proteins or modified forms of proteins and a genomic DNA region. A great 
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advantage is that local chromatin changes can be followed. ChIP can be used to determine 
whether a transcription factor interacts with a candidate target gene or recognizes a certain 
sequence motif in a genome-wide fashion.
43
 The method is used with equal frequency to 
monitor the presence of histones with posttranslational modifications at specific genomic 
locations.  
The first ChIP assay was developed by Gilmour and Lis
44
 as a technique to monitor the 
association of RNA polymerase II with transcribed and poised genes in Drosophila. In those 
early ChIP studies, UV light from a transilluminator was used to crosslink proteins to DNA 
irreversibly. The crosslinked chromatin was then either sonicated or cleaved with restriction 
enzymes to generate smaller DNA fragments, followed by immunoprecipitation with the 
desired antibodies. The precipitated protein-DNA fragments were then purified, treated with a 
protease, and analyzed by dot blot or Southern blot using a radiolabeled probe derived from 
the cloned DNA fragment of interest. These classical ChIP assays required very high amounts 
of material. The use of formaldehyde as a reversible protein-DNA and protein-protein 
crosslinking agent for ChIP and the use of polymerase chain reaction (PCR) to detect 
precipitated DNA fragments were later added as components of the modern ChIP procedure. 
Recently, the ChIP procedure is coupled to massively parallel DNA sequencing to identify the 
binding sites of DNA-associated proteins or PTMs genome wide. Variations of classical ChIP 
include native ChIP that is performed in the absence of crosslinking agents and is used to 
examine proteins that remain stably associated with DNA during chromatin processing and 
immunoprecipitation. Native ChIPs, when performed to detect histone PTMs, can be 
performed with as little as 200 cells as starting material.
45
  
Drug substances can also affect the transcriptional output of chromatin.
46
 They can alter 
chromatin by either directly targeting the DNA backbone or by targeting the proteins 
associated with it. For example, small molecules can interfere or block an epigenetic modifier 
protein interacting with the chromatin and therefore cause ensuing transcriptional changes. 
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Local changes in the methylation level of histones near target genes could be revealed via 
immunoprecipitation after treatment of cells with LSD1 inhibitors.
35,36,4
 Although many drugs 
against epigenetic modifiers have been developed, it still remains unknown to what extent a 
given drug prevents or enhances protein-chromatin interactions. Therefore, an unbiased 
genome-wide approach has been recently established to identify functional targets of small 
molecules in cells and in animals to unravel drug effects across the genome; this technique is 
called Chem-seq.
47
  
Briefly, cultured cells or animals are treated or fed with a biotinylated version of a given small 
molecule. Subsequently, the cells or the tissue from the treated animals are fixed with 
formaldehyde to crosslink DNA, proteins, and the small biotinylated molecules. As in regular 
ChIP, the DNA is extracted, sonicated, and enriched for regions containing the biotinylated 
molecule of interest by incubation with streptavidin magnetic beads. The enriched DNA 
fraction is then purified, eluted from the beads, and subjected to next generation sequencing. 
In contrast to a regular ChIP, where specific antibodies are used, Chem-seq makes use of a 
synthetic compound to identify the genome-wide binding profile of a target molecule.
47
 Both 
methods, illustrated in Fig. 4, can complement each other. For a successful Chem-seq, the 
biotinylated version of the synthetic compound should have a similar strength in binding the 
target as the unmodified drug.  
JQ-1, a well-studied bromodomain inhibitor, binds to the bromodomain family members 
BRD2, BRD3, and BRD4 in MM1.S multiple myeloma cells. Chem-seq profiling of both the 
inhibitor and proteins revealed that BRD4 and JQ-1 co-occupancy occurs at >99% of the 
target genes. In addition, molecules that intercalate with DNA can also be mapped using 
Chem-Seq, e.g., psoralen could be mapped to the transcription start site of active genes.
47
 An 
in vitro variation of the protocol was successfully used for a non-membrane permeable 
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compound. For this, the small biotinylated molecule was added after fragmentation of the 
chromatin.  
Fluorescence resonance energy transfer imaging probes 
The method, developed by Yoshida et al.
48
, to analyze histone acetylation is based on 
conformational changes in a fusion protein of the substrate histone H4 and via a flexible 
linker a bromodomain-containing protein which is further fused with a donor and acceptor 
fluorescent protein. These two fluorescent proteins (CFP and Venus) serve as a FRET system. 
Upon conformational changes in the protein probe, the intramolecular FRET from CFP and 
Venus changes, resulting in a change in signal. The conformational changes occur when the 
bromodomain binds to acetylated substrate histone H4Kac, thereby changes in the acetylation 
level result in a change in signal. Similar FRET imaging probes using different 
bromodomains can be used to visualize different acetylation sites. Yoshida et al. have 
developed two FRET imaging probes, Histac
48
 with the bromodomain BRDT for acetylation 
H4K5/K8 and Histac-K12
49
 with BRD2 for acetylation of H4K12. They have shown that both 
FRET probes incorporate into chromatin without causing apparent abnormalities in the 
nucleosome. Similar acetylation kinetics of the FRET probes and endogenous histone H4 
approved the FRET probes as reversible indicators of H4 acetylation in living cells and target 
engagement has been visualized of various HDAC inhibitors.
49
 As the method has been 
shown to be more sensitive than immunoblot analysis of histone acetylation, it represents a 
powerful tool for HDAC inhibitor target engagement. But not only the cellular response on 
HDAC- or HAT- inhibitors can be analyzed, the technique also serves as a tool to evaluate 
target engagement of small molecules that interact with the bromodomains of FRET probes. 
Histone mass spectrometry 
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The development of high sensitivity methods and their broad application has made mass 
spectrometry a key tool in histone tail modification analysis. However, it is a complex method 
and requires high expertise and modern MS/MS technical equipment with high-resolution 
detector systems. Also, demanding methods for the enrichment of peptides before mass 
spectrometry, such as capillary electrophoresis or reversed phase chromatography, are 
required for reliable results.
50
 Hung et al.
51
 recently published a review about the 
―Quantitative Proteomic Analysis of Histone Modifications‖ to which we want to refer here. 
Chemo-proteomics by mass spectrometry has become a widely used method for the 
determination of selectivity and duration of target engagement. The investigated inhibitor is 
fused to an affinity tag to form a probe. After incubation in a cellular environment, this probe 
enables the isolation of inhibitor-complexes via specific trapping of the affinity tag. The 
methods for quantitative probe-protein complex isolation differ between chemo-proteomic 
methods and depict one of the biggest challenges of the method. Isolated probe-protein 
complexes are analyzed via quantitative mass spectrometry techniques. Thus, ideally, all 
targeted proteins in a cellular proteome of the inhibitor can be identified. Different methods 
have been established for chemo-proteomics approaches, e.g., affinity pull-down, capture 
compound mass spectrometry (CCMS), or activity-based protein profiling. The affinity pull-
down approach uses small molecules like biotin as affinity tags combined with affinity 
chromatography or the inhibitor is immobilized to a solid phase directly. In the capture 
compound mass spectrometry method a third moiety for crosslinking is attached to an 
inhibitor-probe. The covalent crosslinking of probe and targets prevents equilibrium-based 
losses of proteins during affinity purification, resulting in higher selectivity and sensitivity of 
the method. The affinity-based protein profiling method adds a functional reporter tag to the 
inhibitor enabling visualization and enrichment of targets.
52
 Recently, mass spectrometry 
probes for epigenetic inhibitors of deacetylases, bromodomains, demethylases, and 
methyltransferases have been reviewed by Weigt et al.
53
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Generally, inhibitor derived probes should not change the functionality, specificity, or 
potency drastically. Different attachment sites of the sorting moiety on the inhibitor might be 
explored to define structure activity relationships of inhibitor and probes. A phenotypic cell 
response upon probe incubation versus inhibitor ought to be analyzed before proceeding with 
chemo-proteomic experiments.
52
 If structural information is available on the target-inhibitor 
interaction, the probe can be designed rationally.
54
 
 
Functional assays 
These assays cover downstream events in transcription and translation that can be functionally 
tied to the inhibition of epigenetic agents. 
Protein analysis, invasion assay, reporter assay 
Several cancer types show upregulated epigenetic enzymes, which are responsible for 
abnormal gene expression. This phenomenon can be used in inhibitor discovery as treatment 
of cells with the compound leads to changes in downstream gene transcription.
55,56
 Van Lint 
et al.
57
 found changes of 2% in cellular gene expression upon treatment with the HDAC 
inhibitor trichostatin A (TSA) in a lymphoid cell line.  This unique gene change can be used 
as readout for target engagement of an inhibitor. Obviously, the gene change depends highly 
on the cell line and target enzyme subtype. Glaser et al.
58
 even suggests, that gene expression 
depends on the mechanism of inhibition rather than the chemical structure of the inhibitor, 
since they observed different results with the known HDAC inhibitors TSA and vorinostat 
(SAHA) versus entinostat (MS-275). Changes in expression patterns can be observed via 
Western blot, ELISA, q-PCR, microarrays, reporter gene assays, or flow cytometry (FACS), 
and dependent on the method, results may differ. Also, concentration and time of incubation 
influence results. However, as protein expression is controlled by multifaceted processes, a 
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marker as signal of enzyme inhibition has to be chosen carefully and confirmed by several 
positive and negative controls before screening of new compounds can be examined. Two 
examples are Chou et al.,
59
 who reported increased cellular prostatic acid phosphatase 
(cPAcP) levels in prostate cancer upon treatment with the HDAC inhibitor valproic acid, and 
Ward et al.,
60
 who proposed phosphocholine to be a biomarker for HDAC inhibition in breast 
cancer cells. Scoumanne et al.
61
 identified various genes, such as DEK, S100A8, PLCL1, and 
ADAMTS1 regulated by LSD1. As HDACs and LSD1 have been reported to be involved in 
cell cycle progression,
62,61,63
 FACS offers a suitable method for their analysis.
64
 The method is 
highly applied in clinical studies, since only small cell numbers are required. Yu et al.
65
 
observed, upon LSD1 inhibition with pargyline in MCF-7 breast cancer cells, significantly 
reduced E2-mediated S100A7 expression. In addition,  differentiation markers can be 
epigenetically regulated and be examined via FACS. For example, Lynch et al.
66
 ascertained 
the differentiation marker CD86 as a biomarker for LSD1 inhibition in human acute myeloid 
leukemia (THP1 cells). They applied flow cytometry and developed an ELISA. This 
exemplifies the strategy for the development of a cell-based assay with a biomarker as 
surrogate for enzyme inhibition. However, HDAC inhibition has also been associated with 
increased CD86 expression.
67
 Differentiation of cancer and/or stem cells can show the process 
of epithelial-mesenchymal transition (EMT or MET). This process has been found to be 
controlled by epigenetic regulators
68
 and can be observed via cell invasion assays. Invasion is 
defined as cell movement through a 3D matrix. The capability of invasion requires 
modification of cell shape, adhesion, migration, and proteolysis of extracellular matrix 
components. Multiple epigenetic processes have been described in the EMT process, such as 
the interaction of LSD1 with Snail and Slug on the CDH1 promoter; 
69
 also, HDAC1 and 
HDAC2 are involved in the process.
70
 However, more extracellular matrix-related genes are 
regulated by epigenetic enzymes, as reported for HDAC by Whetstine et al.
71
 This makes a 
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cell-based invasion assay a useful tool for epigenetic inhibitor target engagement experiments 
and screening. 
Reporter Assays 
In standard reporter assays, the target enzyme regulates the activity of an expression vector 
via promoter modifications. The promoter is cloned to a reporter gene, which suits as 
selection marker either directly, like GFP, or via an enzyme that catalyzes the formation of a 
quantifiable signal. As bioluminescence of reporter enzyme reactions is more sensitive than 
fluorescent reporters themselves, reporter enzymes became popular and widely used. The 
most commonly applied reporter protein in research is luciferase, which catalyzes the 
conversion of the substrate luciferin in an ATP-dependent manner to the luminescent 
oxyluciferin. However, high-throughput assays usually use the β-lactamase reporter due to 
several advantages, reviewed by Zlokarnik.
72
 For the application in epigenetic drug discovery, 
expression of the reporter genes is correlated to epigenetically regulated promoter activity. 
Martinez et al.
73
 described the establishment of a GFP-reporter assay for HDAC and DNMT 
activity with a CMV promoter. The lack of promoter activity is related to repressive chromatin 
structure, regulated via HDAC activity. Recently, this GFP-reporter assay has been used for 
screening and identification of new HDAC inhibitors.
77
 Another example is the promoter of 
p21, which is associated with HDAC binding sites.
74
 The HDAC inhibitor program of 
Novartis that led to the approval of panobinostat for the treatment of multiple myeloma, 
originated from a campaign that was looking for compounds that induce the overexpression of 
p21.
75
 Several promoters have also been found to be regulated by LSD1, e.g., BAT gene 
promoters
76
 or the mouse PGC-1α promoter.78 The challenge with histone modifying enzyme 
is the incorporation of the transgene into the nucleosome. Only stable transfection enables the 
cloned gene construct to engage with histones, which can be verified in Chip experiments. 
However, this challenge can be avoided when the function of a target enzyme as a mediator in 
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a signal pathway is used for the regulation of the promoter of a reporter gene, e.g., reporter 
constructs of the TGFβ signaling pathway for HDAC inhibitor screenings.79 As LSD1 is 
involved in estrogen- and androgen-receptor regulation, ERα-80 and androgen-receptor81-
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Once a reporter assay has been established, screening can be done easily and high-throughput 
assays are possible, which was implemented by Ashburner et al.
82
 with a NF-κB-dependent 
reporter gene. Before reporter assays are performed for inhibitor testing, compound effects on 
cell growth are usually assessed. Strong anti-proliferative action would show a 
downregulation of the reporter, leading to either false positive or false negative results. This 
problem can be avoided when dual reporter assays are established, where a second reporter is 
used to normalize gene expression and, thus, cytotoxic effects are noticed. One important 
complication can be direct inhibitors of luciferase, which lead to an increased luciferase 
activity. This is counterintuitive but can be explained by stabilization of the enzyme in the 
workup.
83
 Thus, the hits from an enzymatic reporter gene assay always need to be counter-
screened for an influence on the reporter´s activity. 
 
Phenotypic Assays 
Phenotypic assays are methods where the effect of compounds is measured with a relatively 
simple global readout in a cellular setting. Phenotypic assays allow the capture of information 
about the reaction of a complex system to a compound. These assay systems can screen for 
proliferation or viability of cells, cytotoxicity, apoptosis, differentiation, and control of cell 
cycle. Since epigenetic modifications regulate gene expression, all of these global processes 
can be affected by inhibitors of epigenetic targets. 
Proliferation, viability, and cytotoxicity assays 
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MTS assay (CellTiter 96
®
 AQueous One Solution Cell Proliferation Assay) 
The MTS assay is a standard colorimetric method to quantify the viability of cells after they 
have been incubated with a compound at specific concentrations. Viability is measured via the 
conversion of the substrate MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium, inner salt] with an electron coupling reagent (phenazine 
ethosulfate, PES, or phenazine methosulfate, PMS,) by NAD(P)H-dependent dehydrogenases 
in metabolically active cells, as portrayed in Fig. 5. The formazan product is quantified by 
measuring its absorbance of light with a wavelength of 490 nm. Cell viability is directly 
proportional to the amount of absorbance at 490 nm.
84
 Compounds have to be removed before 
the measurement to exclude false results due to the possibility of their absorbance at 490 nm. 
Through incubating cells at different concentrations of the same compound, determinations of 
GI50-values are possible.  
Other assay systems, such as the CellTiter-Blue®Cell Viability Assay (resazurin) or 
CellTiter-Glo® Luminescent Cell Viability Assay, exist to determine cytotoxicity or viability 
of cells.
84
 The MTS assay procedure is easy and fast to perform, which makes it a widely 
applied assay system, also for high-throughput screening. Many publications show growth 
arrest of cancer cells after HDAC inhibition due to diverse reasons, such as apoptosis, 
autophagy, or senescence.
19,56
 However, LSD1 inhibition has been reported to be insensitive 
to cell proliferation or viability.
85
 Mohammad et al.
86
 monitored proliferation of more than 
150 cancer cell lines during incubation with an LSD1 inhibitor and found only acute 
monocytic leukemia (AML) and some small cell lung cancer (SCLC) cell lines to be sensitive. 
Nevertheless, reduced cell numbers have been observed upon LSD1 knockout in breast cancer 
cells after extended incubation times comparable to colony formation assays.
87
 Since 
apoptosis and cell arrest are not specific readouts for a specific enzyme, off-target effects 
cannot be discriminated from target engagement effect in MTS assays, especially when high 
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compound concentrations are applied. It is not clear yet if all types of Jumonji-demethylase 
inhibitors reduce proliferation of all cell types. Many publication show the effect; however, 
Itoh et al.,
88
 for example, only observed reduced cell growth when cells were incubated with 
their inhibitors in combination with the HDAC inhibitor vorinostat and, thus, off-target effects 
might also be the reason for cell death. Still, a phenotypic screen for the reversal of ras-
transformed cells by Fujisawa was the basis for the discovery of the HDAC inhibitor 
romidepsin, which is approved for the treatment of cutaneous and peripheral T-cell lymphoma 
(CTCL and PTCL).
89
 
Colony formation assays  
Clonogenic assays utilize the ability of single cells to undergo unlimited division and 
proliferate into a clonogenic colony of at least 50 cells.
90
 Changes in the chromatin structure 
can result in the loss of this ability. Thus, this method offers a platform to screen epigenetic 
compounds. In the assay, cells are usually incubated for 10-20 days. During this prolonged 
incubation, all forms of cell death and the ability to proliferate have an impact on the readout. 
LSD1 inhibition results in gene modulation, which affects the clonogenic potential of cancer 
cells. Therefore, colony formation assays can be applied to test potential LSD1 inhibitors on 
their effect on cells. Cells can be treated before or after plating single cells on a petri dish
91
 or 
special semi solid matrix for suspension cells.
92
 
The incorporation of several mechanisms in a single readout indicates colony formation 
assays results are closer to the in vivo situation than viability assays. However, the conditions 
of the isolated cells in a petri dish with growth media and normalized oxygen concentrations 
still vastly differ from the environment of a cancer cell in vivo.
90
  
 
Issues with chemical probes 
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Characterization of chemical probes 
In using epigenetic chemical probes described in the literature, a major issue is the lack of 
detail provided. Of course, this is often unavoidable when a new chemical probe is published 
and one has to wait for independent verification from other groups. Until then, the validity of 
the probe primarily comes from mechanism-based in vitro assays that measure its affinity for 
the desired target. Nowadays, kits are commercially available for many epigenetic targets and 
batch to batch variation can compromise assay results. Furthermore, all assays are prone to 
artefacts and interfering agents and the published literature should be carefully read to 
understand if such possibilities were considered for the new probe. Should the data for target 
affinity appear robust, then the next question is the probe’s selectivity against related targets 
and the evidence for target engagement in cells or in vivo. A poorly characterized probe is not 
necessarily a bad one and many that were originally not described in much detail have gone 
on to be highly successful and widely used. However, should there be an absence of extensive 
literature regarding the probe, one should proceed with caution and the fact that it may be sold 
by catalogue companies should not be taken generally as an endorsement of its validity. 
Santacruzamate A (1) is a marine natural product that was recently isolated from a Symploca 
sp. marine cyanobacterium and bears a superficial resemblance to the clinically approved 
HDAC inhibitor vorinostat (2). Based on assay kits, santacruzamate A has a reported IC50 of 
0.11 nM against HDAC2, 433 nM against HDAC4, and >1 µM against HDAC6.
93
 The high 
level of activity against HDAC2 and the selectivity are both surprising, given the absence of 
an obvious zinc-binding warhead typical of HDAC inhibitors and the simplicity of the 
structure. Although no evidence for cellular target engagement was provided, the compound 
was patented and sold by catalogue companies. Ganesan and Wen synthesized santacruzamate 
A and a set of analogues, which all proved to be inactive in HDAC assays.
94
 The original 
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report was clearly mistaken although the compound continues to be available as an isoform-
selective HDAC inhibitor.  
A series of synthetic aurones was reported as HDAC inhibitors, exemplified by (3) with an 
IC50 of 8 µM against HDACs from HeLa nuclear extracts, 11 µM against HDAC1, 5 µM 
against HDAC2, and 27 µM against HDAC6.
95
 Evidence for target engagement came from 
measurements of histone H3 acetylation in living cells using a bioluminescent resonance 
energy transfer technology (BRET)-based assay. Subsequently, Suzuki has shown that the 
aurone is a strong quencher of fluorescence in the HDAC assays and found no evidence for 
increased H3K9 or tubulin acetylation by Western blotting.
96
 Recently, the same authors who 
reported the aurones have identified hyrazide (4) as a non-hydroxamic acid selective HDAC 
inhibitor with an IC50 of 13 µM against HDAC6 in the fluorescent assay.
97
 The only evidence 
for target engagement was increased tubulin acetylation levels and further investigation is 
necessary to substantiate these claims given the unprecedented nature of hydrazides as zinc 
binding warheads in HDAC inhibitors. 
Through screening of a compound library, the natural product chaetocin (5) was identified as 
a lysine methyltransferase inhibitor. The initial profiling suggested the compound was a 
specific inhibitor of SU(VAR)3-9 methyltransferase, competitive with the enzyme cofactor 
SAM, and the activity was unrelated to the presence of the disulfide bridge.
98
 Later studies by 
Fuchter with chaetocin and synthetic analogues suggest these compounds react with the 
enzyme in a time-dependent and nonspecific manner and are not competitive with SAM.
99,100
 
There is data that chaetocin is a selective inhibitor within a certain concentration range,
101
 but, 
given the chemical reactivity of disulfides and their propensity for nonselective reaction with 
protein thiol residues, it—and other members of this class—should not be the first choice of 
cellular probes for methyltransferases. 
Selectivity and target affinity of chemical probes 
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Besides probes that are poorly characterized, another major issue arises from probes that are 
poor in selectivity. Some of these compounds may have robust and reproducible evidence 
from multiple laboratories to support engagement with an epigenetic target and even 
advanced to clinical development as therapeutic agents on this basis. Nevertheless, the fact 
remains that their target affinity is relatively modest (micromolar to almost millimolar) and 
the data is based on experiments using high concentrations of the probe. At such levels, there 
are likely to be off-target effects and, indeed, it is a common feature of such molecules to be 
associated with multiple unrelated targets. While some might consider such promiscuity 
beneficial, it will confound the interpretation of cellular assays and there needs to be 
convincing evidence that the phenotypic effects can be attributed to the epigenetic target. 
Butyric acid (6), as the sodium salt, was the first HDAC inhibitor to be identified and this led 
to studies with other short chain fatty acids. Valproic acid (7), for example, is an approved 
drug for the treatment of epilepsy and it works primarily as a blocker of voltage-dependent 
sodium channels for this indication. In addition, the compound is a HDAC inhibitor with a 
reported IC50 of 400 µM against HDAC1.
102
 There are numerous reports investigating 
valproic acid, butyric acid and phenylbutyric acid (8) as HDAC inhibitors and, on this basis, 
the compounds are undergoing clinical trials as anticancer agents. Nevertheless, all these 
compounds have an IC50 > 100 µM and are likely to exhibit polypharmacology, which needs 
to be taken into account in the interpretation of biological experiments. Certainly, it is 
difficult to understand why these fatty acids continue to be widely used as chemical probes of 
HDAC function, while a plethora of inhibitors, such as hydroxamic acids, benzamides, or the 
disulfide-containing romidepsin, have IC50 values that are 1,000-fold higher in potency. 
Depudecin (9) is another probe sold as a HDAC inhibitor although the relatively high IC50 of 
5 µM in the original report
103
 and the presence of reactive epoxide functionality do not 
promote confidence in its application as a selective chemical probe. 
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Extensive polypharmacology is a common feature of dietary chemicals. Rather than potently 
inhibiting a single protein, these natural products tend to interact with large numbers of 
targets. While this might be useful nutritionally and help provide a therapeutic benefit when 
taken as dietary mixtures, such compounds in their pure state are poor choices as selective 
cellular probes and more likely to result in pain.
104
 Curcumin (10) from turmeric, 
epigallocatechin gallate (11) from green tea, and quercetin (12) in fruits and vegetables, for 
example, are reported to modulate multiple epigenetic pathways albeit at high 
concentrations.
105
 
 
Recently, the flavone chrysin (13), which is even simpler in structure than quercetin, was 
screened against HDAC isoforms and found by two groups to selectively inhibit 
HDAC8,
106,107
 with one reporting an IC50 of 40 µM with HDAC8 and 120 µM with HDAC2. 
This level of selectivity for a simple flavone that does not contain a high-affinity zinc-binding 
warhead is unexpected. In support of target engagement, both groups showed p21 induction, 
although changes in histone H3 acetylation levels were contradictory. The compound 
displayed antitumor activity in vivo in a xenograft model, although further work is necessary 
to prove if this is primarily due to HDAC inhibition and if it is indeed isoform-selective. 
Resveratrol (14) was initially reported as a sirtuin activator, although this is now 
controversial.
108
 At a high concentration of 100 µM, it appears to inhibit all HDAC isoforms 
by 15-50%, although the physiological relevance at such high levels is moot.
109
 The saturated 
anacardic acid (15), a byproduct from cashew nut shell oil, was reported as a micromolar 
inhibitor of the p300 histone acetyltransferase.
110
 The molecule’s high lipophilicity, its ability 
to act as a surfactant, and extensive literature on other targets
111
 suggest its biological effects 
are at best complex in nature. 
Strategy for avoiding issues with chemical probes 
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When selecting an epigenetic chemical probe, it is helpful to go through a checklist (Table 1) 
before making a decision. 
1. Does the probe have a high affinity (<1 µM) for the target? 
For some epigenetic targets, there is no choice as the best probes do not reach this level of 
affinity. However, if you are working on a target for which higher affinity probes are 
available, there must be a good reason for selecting one with lower affinity. 
2. Is there evidence of target engagement in cellular or in vivo models? 
This is critical in the choice of probe. Ideally, there should be supporting evidence of target 
engagement from multiple experiments and multiple laboratories. 
3. Is the probe selective for a particular member of the epigenetic target family? 
The importance of this question lies in the biology that is being investigated. For example, if 
you are interested in bromodomains generally, a nonspecific ligand like bromosporine would 
be a good choice. Conversely, if selectivity for the BET subfamily of bromodomains is 
required, then a ligand like JQ1 would be preferable. 
4. Are compounds available for control experiments? 
If a biological effect is observed with the probe, it should be reproducible by a chemically 
unrelated probe for the same epigenetic target. On the other hand, a probe analogue that is 
inactive is a highly useful negative control. This may, for example, involve switching a 
hydroxamic acid HDAC inhibitor for the corresponding amide or ester that would have much 
weaker affinity for the enzyme. Stereochemical switches are another option, as the 
enantiomers of JQ1 or i-BET ligands are equivalent in chemical connectivity and functional 
groups but are inactive in binding to the bromodomain. 
5. Is the probe well documented in the literature? 
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As time goes by, a good probe will receive multiple citations and these should be examined 
for further information regarding its affinity and selectivity. Inevitably, the more the probe 
gets used, the more will be reported about its off-target effects. Having this knowledge allows 
one to decide whether these are relevant or not to the planned experiments and is preferable to 
using a new probe which appears clean simply because it has not been thoroughly 
investigated. Natural products may have an additional concern due to minor impurities that 
lead to false activity and this may be resolved only when the compound is independently 
made synthetically. 
Table 1: Five questions for epigenetic probe selection. 
1. Does the probe have a high affinity (<1 µM) for the target? 
2. Is there evidence of target engagement in cellular or in vivo models? 
3. Is the probe selective for a particular member of the epigenetic target family? 
4. Are additional compounds available for control experiments? 
5. Is the probe well documented in the literature? 
 
 
Conclusions 
Many methods are available to characterize the cellular effects of epigenetic inhibitors.
112
 
These methods are applied to cultured cells, possibly also to animal samples as well as patient 
derived material. Some directly measure target engagement while others monitor downstream 
events. For an enzyme the next closest readout is the change of a level in substrate abundance, 
then effects on gene transcription and protein biosynthesis can be monitored subsequently, 
which ultimately culminate in changes of phenotypic properties, such as cell differentiation, 
apoptosis, or viability. The further away the assay is from the direct target of course the 
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higher the chance that other effects lead to the same downstream response. For example, 
standard cytotoxic agents such as ethanol may also lead to tubulin hyperacetylation just like 
specific HDAC6 or Sirt2 inhibitors do.
113
 
Thus, it is very important to be critical regarding the level of information that a cellular test 
provides and alternative explanations for a given readout should be considered. Still, cellular 
assays can be very useful for the discovery and characterization of new epigenetic drugs. 
Ideally, the whole chain of assays from in vitro biochemistry, target engagement, and 
functional and phenotypic assays is performed and good positive and negative controls are 
used to support the implications drawn from such assays. 
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[Figure 1: Overview of different approaches for cellular characterization of potential 
epigenetic modulators]. 
 
 
 
 
 
 
  47 
 
[Figure 2: Trypsin-coupled HDAC Assay18] 
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[Figure 3: Schematic illustation of protein stability upon heat exposure. Small molecules 
bound to a protein can result in increased protein stability. CETSA experiments take 
advantage of this effect.] 
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[Figure 4: Comparative illustration of the methods ChIP-seq and Chem-seq.] 
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[Figure 5: Illustration of the MTS Assay for determination of cytotoxicity.] 
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[Figure 6: structures of santacruzamate A (1) and vorinostat (2)] 
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[Figure 7: Structure of 3, 4 and chaetocin (5)  ] 
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[Figure 8: structure 6, 7, 8, and 9] 
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[Figure 9: structure of curcumin, epigallocatechin gallate and quercetin] 
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[Figure 10: structure of chrysin, resveratrol, anacardic acid] 
 
